Swollen right hand in a female patient during a hereditary angioedema attack. Credit: LucyHAE.

Shire has reported positive results from the Phase III hereditary angioedema long-term prophylaxis (HELP) trial assessing the efficacy and safety of subcutaneously administered lanadelumab for the treatment of hereditary angioedema (HAE).

HAE is a rare genetic disorder that can cause recurrent attacks of oedema in several parts of the body.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial met its primary and secondary endpoints in demonstrating that patients treated with lanadelumab 300mg every two weeks had significantly fewer HAE attacks and were less likely to have moderate / severe attacks or use rescue medication.

Patients receiving lanadelumab 300mg were also more likely to be HAE attack-free than those receiving placebo.

“For those living with this chronic and unpredictable disease, it is important that they can reduce the frequency of their HAE attacks.”

This data was observed throughout the trial’s 26-week treatment period and as per post hoc sensitivity analysis.

Interim results from the HELP study’s open-label extension phase showed that treatment with lanadelumab was generally well-tolerated and similar to the previous safety profile.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the interim analysis, patients were treated with lanadelumab for a mean period of 8.21 months and continued to experience a reduction in HAE attacks.

Shire executive vice-president and research and development head Andreas Busch said: “For those living with this chronic and unpredictable disease, it is important that they can reduce the frequency of their HAE attacks.

“Additional analysis of the HELP study continues to support the use of lanadelumab as a preventive subcutaneous treatment option for HAE in appropriate patients 12 years of age and older.”

The trial was conducted in a multi-centre, randomised, double-blind, placebo-controlled parallel group setting and included 125 HAE patients aged 12 years or older.

Shire is a biopharmaceutical company based in Ireland.